Eisai Co., Ltd. - Product Pipeline Review - 2015

Date: October 30, 2015
Pages: 184
Price:
US$ 1,500.00 US$ 1,200.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: EF4066D0F55EN
Leaflet:

Download PDF Leaflet

Eisai Co., Ltd. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Eisai Co., Ltd. - Product Pipeline Review - 2015’, provides an overview of the Eisai Co., Ltd.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Eisai Co., Ltd.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides brief overview of Eisai Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Eisai Co., Ltd.’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Eisai Co., Ltd.’s pipeline products
Reasons to buy
  • Evaluate Eisai Co., Ltd.’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Eisai Co., Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Eisai Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Eisai Co., Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Eisai Co., Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
  • Explore the dormant and discontinued projects of Eisai Co., Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues
Eisai Co., Ltd. Snapshot
Eisai Co., Ltd. Overview
Key Information
Key Facts
Eisai Co., Ltd. - Research and Development Overview
Key Therapeutic Areas
Eisai Co., Ltd. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Pipeline Products - Partnered Products
Pipeline Products - Out-Licensed Products
Eisai Co., Ltd. - Pipeline Products Glance
Eisai Co., Ltd. - Late Stage Pipeline Products
Eisai Co., Ltd. - Clinical Stage Pipeline Products
Eisai Co., Ltd. - Early Stage Pipeline Products
Eisai Co., Ltd. - Drug Profiles
cinitapride
eribulin mesylate
lenvatinib
lorcaserin hydrochloride
mecobalamin
mitiglinide
perampanel
clevudine
donepezil hydrochloride Patch
(diclofenac sodium + eperisone)
avatrombopag
BAN-2401
decitabine
denileukin diftitox
donepezil hydrochloride
E-2609
E-3710
E-6005
E-7820
eritoran tetrasodium
fosravuconazole
indisulam
irofulven
lemborexant
rabeprazole sodium DR
Vaccine for Metastatic Melanoma
bexarotene
E-6011
E-6201
E-7449
golvatinib + lenvatinib
golvatinib tartrate
tazemetostat
E-2027
E-6007
E-7046
E-7090
E-7389LF
AT-791
E-1210
E-2072
E-2508
E-5539
E-6446
ER-358063
ER-409903
ER-410660
ER-417258
ER-886046
ER-901356
Monoclonal Antibody to Inhibit CCL20 for Arthritis and Contact Hypersensitivity
SJ-733
Small Molecule to Antagonize CRF-1 Receptor for Anxiety Disorders
Small Molecule to Inhibit Cytidine Deaminase for Cancer
Small Molecule to Inhibit GWT1 Protein for Malaria
Small Molecules for Bacterial Infections
Small Molecules for Chagas Disease
Small Molecules for Lymphatic Filariasis and Onchocerciasis
Small Molecules for Malaria
Small Molecules for Oncology
Small Molecules for Tuberculosis
TRI-4
Eisai Co., Ltd. - Pipeline Analysis
Eisai Co., Ltd. - Pipeline Products by Target
Eisai Co., Ltd. - Pipeline Products by Route of Administration
Eisai Co., Ltd. - Pipeline Products by Molecule Type
Eisai Co., Ltd. - Pipeline Products by Mechanism of Action
Eisai Co., Ltd. - Recent Pipeline Updates
Eisai Co., Ltd. - Dormant Projects
Eisai Co., Ltd. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Eisai Co., Ltd. - Company Statement
Eisai Co., Ltd. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Eisai Co., Ltd., Key Information
Eisai Co., Ltd., Key Facts
Eisai Co., Ltd. - Pipeline by Indication, 2015
Eisai Co., Ltd. - Pipeline by Stage of Development, 2015
Eisai Co., Ltd. - Monotherapy Products in Pipeline, 2015
Eisai Co., Ltd. - Combination Treatment Modalities in Pipeline, 2015
Eisai Co., Ltd. - Partnered Products in Pipeline, 2015
Eisai Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2015
Eisai Co., Ltd. - Out-Licensed Products in Pipeline, 2015
Eisai Co., Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2015
Eisai Co., Ltd. - Pre-Registration, 2015
Eisai Co., Ltd. - Filing rejected/Withdrawn, 2015
Eisai Co., Ltd. - Phase III, 2015
Eisai Co., Ltd. - Phase II, 2015
Eisai Co., Ltd. - Phase I, 2015
Eisai Co., Ltd. - Preclinical, 2015
Eisai Co., Ltd. - Discovery, 2015
Eisai Co., Ltd. - Pipeline by Target, 2015
Eisai Co., Ltd. - Pipeline by Route of Administration, 2015
Eisai Co., Ltd. - Pipeline by Molecule Type, 2015
Eisai Co., Ltd. - Pipeline Products by Mechanism of Action, 2015
Eisai Co., Ltd. - Recent Pipeline Updates, 2015
Eisai Co., Ltd. - Dormant Developmental Projects,2015
Eisai Co., Ltd. - Discontinued Pipeline Products, 2015
Eisai Co., Ltd., Subsidiaries

LIST OF FIGURES

Eisai Co., Ltd. - Pipeline by Top 10 Indication, 2015
Eisai Co., Ltd. - Pipeline by Stage of Development, 2015
Eisai Co., Ltd. - Monotherapy Products in Pipeline, 2015
Eisai Co., Ltd. - Combination Treatment Modalities in Pipeline, 2015
Eisai Co., Ltd. - Partnered Products in Pipeline, 2015
Eisai Co., Ltd. - Out-Licensed Products in Pipeline, 2015
Eisai Co., Ltd. - Pipeline by Top 10 Target, 2015
Eisai Co., Ltd. - Pipeline by Top 10 Route of Administration, 2015
Eisai Co., Ltd. - Pipeline by Top 10 Molecule Type, 2015
Eisai Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015
Skip to top


Ask Your Question

Eisai Co., Ltd. - Product Pipeline Review - 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: